Science
Mechanism of Action
This extract functions by dose-dependently modulating critical inflammatory pathways. It significantly reduces the expression of the cathelicidin gene (LL37), a peptide implicated in conditions such as rosacea and psoriasis, with reported reductions of up to 40% under IL-17 induction and 27% under calcitriol induction. Beyond its anti-inflammatory action, it actively regulates angiogenesis, counteracting pro-angiogenic factors like LL-37, IL-17, and vitamin D3 to mitigate visible signs of vascular distress and promote overall skin health, leaving it soft and smooth.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Clinical evaluations at concentrations of 0.3% and 0.5% demonstrated that compositions containing Tambourissa Trichophylla leaf extract effectively reduced cathelicidin gene (LL37) expression. This led to significant improvements in symptoms associated with rosacea, couperosis, erythrosis, telangiectasia, and generalized skin redness and blotchiness by exerting anti-inflammatory and angiogenesis-regulating effects.
Transparency
Dusting Analysis
The Formula
Formulation
Safety
Safety Profile
The Cosmetic Ingredient Review (CIR) identified 'Tambourissa Trichophylla Leaf Extract' as a 'Zero use ingredient with Insufficient Data' in September 2010. There is currently no specific CIR review or safety assessment available for 'Tambourissa Trichophylla Bark Extract', and other industry bodies like Paula's Choice and EWG also report insufficient research for a definitive rating.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While initial clinical data suggests promising efficacy in reducing inflammation and redness, the current lack of comprehensive safety data from authoritative bodies like CIR necessitates caution.
Related
Similar Ingredients
Finding similar ingredients…